Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb;74(2):469-471.
doi: 10.1016/j.jhep.2020.09.027. Epub 2020 Oct 20.

Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points

Marcos F Fondevila  1 , Maria Mercado-Gómez  2 , Amaia Rodríguez  3 , Maria J Gonzalez-Rellan  1 , Paula Iruzubieta  4 , Víctor Valentí  3 , Javier Escalada  3 , Markus Schwaninger  5 , Vincent Prevot  6 , Carlos Dieguez  1 , Javier Crespo  4 , Gema Frühbeck  3 , Maria L Martinez-Chantar  7 , Ruben Nogueiras  8
Affiliations
Comment

Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points

Marcos F Fondevila et al. J Hepatol. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Fig. 1
Fig. 1
ACE2 and TMPRSS2 hepatic mRNA levels in patients with T2D or NAFLD. (A) ACE2 and TMPRSS2 expression in obese patients with T2D (n = 43) or NG (n = 51); and (B) separately by men and women with T2D or NG. (C) ACE2 and TMPRSS2 expression in obese patients without NAFLD (n = 17), steatosis (n = 57), NASH (n = 20). (D) Correlation between ACE2 and TMPRSS2 with NAS score. ∗p <0.05, ∗∗p <0.01, Mann-Whitney U test (A, B), Krustal-Wallis followed by Dunn post-hoc test (C). ACE2, angiotensin converting enzyme 2; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NG, normoglycemia; T2D, type 2 diabetes; TMPRSS2, transmembrane protease serine 2.
See this image and copyright information in PMC

Comment on

Dataset use reported in

References

    1. Biquard L., Valla D., Rautou P.E. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. J Hepatol. 2020;73(3):717–718. - PMC - PubMed
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8. - PMC - PubMed
    1. Ji D., Qin E., Xu J., Zhang D., Cheng G., Wang Y. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73:451–453. - PMC - PubMed
    1. Zhou Y.J., Zheng K.I., Wang X.B., Yan H.D., Sun Q.F., Pan K.H. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020;73:719–721. - PMC - PubMed
    1. Zhou Y.J., Zheng K.I., Wang X.B., Sun Q.F., Pan K.H., Wang T.Y. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020 - PMC - PubMed